Oxonol, MGM-15 and DEA Scheduling: August 2026 Status

DEA's August 26, 2026 temporary order is relevant to Oxonol because the manufacturer description cited here identifies MGM-15 in the formula. The federal order names MGM-15 rather than the retail brand and places the named substance in Schedule I.

The August 26 document is the effective temporary order

DEA's temporary order placed MGM-15, MGM-16, and mitragynine pseudoindoxyl in Schedule I effective August 26, 2026. The order remains effective through August 26, 2028 unless it is extended or made permanent.

The procedural distinction now runs in the other direction: describing the July notice of intent without the August order is incomplete. The separate proposed-threshold process for 7-OH has not been made effective by this three-substance order.

Why the brand name does not decide coverage

Federal scheduling documents identify substances, their chemical names, and covered forms. They cannot be expected to list every retail brand. The manufacturer says Oxonol is its brand name for tablets containing MGM-15 and mitragynine. Therefore the useful question is whether the current product contains the named substance MGM-15, not whether “Oxonol” appears in the notice.

What DEA says MGM-15 is

The notice identifies MGM-15 as dihydro-7-hydroxymitragynine. It describes MGM-15, MGM-16, and mitragynine pseudoindoxyl as synthetic derivatives of plant alkaloids and says MGM-15 is produced through synthetic modification of purified mitragynine isolates or 7-hydroxymitragynine. The document separately acknowledges mitragynine and 7-hydroxymitragynine as naturally occurring in the plant.

Why DEA is treating MGM-15 as more than a naming issue

Commercial MGM-15 tablets are intended for ingestion. Peer-reviewed analysis found an average of 10.9 milligrams of MGM-15 in tested tablets and greater human mu- and delta-opioid-receptor binding affinity than 7-OH. No controlled human-administration studies have established a safe amount, clinical benefit, or predictable adverse-event rate.

Strong receptor activity, products intended for human consumption, and limited human-safety evidence help explain the scheduling action. Impairment, tolerance, dependence, and withdrawal remain credible concerns; receptor results do not establish a therapeutic use or predictable human dose.

How this relates to the separate 7-OH action

The two federal lanes no longer share the same procedural status. DEA's August 26 order is effective for MGM-15, MGM-16, and mitragynine pseudoindoxyl. The proposed threshold for 7-OH remains a separate process. Describing a formulation as structurally different from 7-OH does not answer whether it contains MGM-15 or another substance covered by the effective order.

The August 26 Federal Register order supplies the controlling scope and dates for MGM-15, MGM-16, and mitragynine pseudoindoxyl. The HHS extension documents the separate deadline for information on the proposed 7-OH threshold.

What should be checked next

• Federal order: read the effective August 26, 2026 temporary order and check for any extension or permanent action.
• Current formula: verify whether the manufacturer continues to identify MGM-15 in Oxonol.
• State and local rules: federal timing does not replace jurisdiction-specific checks.
• Inventory and records: businesses should preserve invoices, labels, formulas, lot records, and dated legal guidance.

Where MIT fits

MIT means mitragynine and is not named among the three substances in the MGM-15 notice. It is a separate naturally occurring alkaloid identity, even when concentrated into an extract. That does not make an MIT product FDA approved or exempt from every possible rule. It does make MIT different from an MGM-15 formulation at the ingredient level.

Kratom Paradise's MIT tablets and powders are labeled and organized around mitragynine, not Oxonol or an MGM-series derivative. That supports a direct ingredient-and-document comparison, but it does not make MIT interchangeable with MGM-15 or establish a medical, legal, or safety advantage.

Keep the status dated

Federal status can change after publication. Check the Kratom Paradise scheduling tracker and the linked government records for a later order. For additional context, read What Is Oxonol? and the Oxonol vs MIT vs 7-OH comparison.

For product and regulatory education only; not medical or legal advice.